Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

16.510
-0.780-4.51%
Volume:8.50M
Turnover:140.91M
Market Cap:43.90B
PE:11.12
High:17.200
Open:17.200
Low:16.360
Close:17.290
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:1.49
T/O Rate:1.57%
Dividend:0.46
Dividend Rate:2.76%
EPS(LYR):1.485
ROE:6.95%
ROA:1.40%
PB:0.77
PE(LYR):11.12
PS:0.88

Loading ...

Pharmaceutical Firms Divest Assets to Bolster Core Operations

Deep News
·
Yesterday

Fosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials

Deep News
·
Yesterday

Fosun Pharma Repurchases 152,500 H-Shares for HK$2.63 Million on 9 September 2026

Bulletin Express
·
Yesterday

Fosun Pharma Spends HK$2.63 Million Buying Back Shares on September 9

Stock News
·
Yesterday

Sinopharm Group Stock Slips 2.1% in Hong Kong

Dow Jones
·
Yesterday

Fosun Pharma Receives NMPA Approval to Launch Phase II/III Trial for Dual JAK/TYK2 Inhibitor FXS5626 in Non-Segmental Vitiligo

Bulletin Express
·
Sep 08

Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626

THOMSON REUTERS
·
Sep 08

Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication

Stock News
·
Sep 08

Fosun Pharma Repurchases 70,000 H Shares for HKD 1.18 Million, Trimming Free Float by 0.01%

Bulletin Express
·
Sep 07

Fosun Pharma Spends HK$1.18M on Share Buyback on September 7

Stock News
·
Sep 07

Sinopharm Group Stock Rallies 0.9% in Hong Kong

Dow Jones
·
Sep 07

Fosun Pharmaceutical Extends Deadline of 81 Million Yuan Shareholder Loans to Fuyun Health; Shares Up 7%

MT Newswires Live
·
Sep 07

AI-Powered Drug Discovery Heats Up as Innovative Medicines Race Accelerates in Hong Kong Markets

Stock News
·
Sep 07

Shanghai Fosun Pharma 2196.hk Says it Plans to Buy Back up to HK$1Bln of Company H-Shares

THOMSON REUTERS
·
Sep 06

Fosun Pharma Announces HK$1.00 Billion H-Share Buyback Plan for 2026

Bulletin Express
·
Sep 06

Fosun Pharma's Unit to Trim Stake in Gland Pharma via Share Sale

Stock News
·
Sep 06

Sinopharm Group Stock Advances 1.5% in Hong Kong

Dow Jones
·
Sep 04

Fosun Pharma Receives NMPA Nod for Luvometinib’s Adult NF1 Plexiform Neurofibroma Indication

Bulletin Express
·
Sep 03

Shanghai Fosun Pharma - Drug Registration Application for Additional Indication of Luvometinib Tablets of Unit Approved by Nmpa China

THOMSON REUTERS
·
Sep 03

Shanghai Fosun Pharmaceutical Secures Regulatory Nod for Expanded Use of Lung Cancer Drug

Stock News
·
Sep 03